Alphamab Oncology Future Growth
Future criteria checks 2/6
Alphamab Oncology is forecast to grow earnings and revenue by 1.6% and 37.5% per annum respectively. EPS is expected to grow by 1.7% per annum. Return on equity is forecast to be -11.2% in 3 years.
Key information
1.6%
Earnings growth rate
1.7%
EPS growth rate
| Biotechs earnings growth | 35.6% |
| Revenue growth rate | 37.5% |
| Future return on equity | -11.2% |
| Analyst coverage | Low |
| Last updated | 08 May 2024 |
Recent future growth updates
Recent updates
Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up
May 06
Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking
Mar 13Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price
Jan 17Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch
May 21Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts
Mar 01Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?
Oct 04Is Alphamab Oncology (HKG:9966) A Risky Investment?
May 21Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt
Oct 05Is Alphamab Oncology (HKG:9966) Using Too Much Debt?
May 05How Many Alphamab Oncology (HKG:9966) Shares Have Insiders Sold, In The Last Year?
Feb 09
Should Alphamab Oncology (HKG:9966) Be Disappointed With Their 19% Profit?
Dec 30What Percentage Of Alphamab Oncology (HKG:9966) Shares Do Insiders Own?
Nov 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 632 | -170 | -126 | -74 | 3 |
| 12/31/2025 | 373 | -377 | -343 | -306 | 3 |
| 12/31/2024 | 239 | -299 | -287 | -251 | 3 |
| 12/31/2023 | 219 | -211 | -239 | -203 | N/A |
| 9/30/2023 | 234 | -214 | -277 | -215 | N/A |
| 6/30/2023 | 250 | -218 | -315 | -228 | N/A |
| 3/31/2023 | 208 | -272 | -372 | -264 | N/A |
| 12/31/2022 | 167 | -326 | -430 | -300 | N/A |
| 9/30/2022 | 183 | -309 | -423 | -275 | N/A |
| 6/30/2022 | 200 | -292 | -416 | -251 | N/A |
| 3/31/2022 | 173 | -352 | -447 | -286 | N/A |
| 12/31/2021 | 146 | -412 | -479 | -321 | N/A |
| 9/30/2021 | 73 | -502 | -499 | -368 | N/A |
| 6/30/2021 | N/A | -592 | -519 | -415 | N/A |
| 3/31/2021 | N/A | -510 | -478 | -381 | N/A |
| 12/31/2020 | N/A | -428 | -438 | -347 | N/A |
| 9/30/2020 | 1 | -652 | -422 | -305 | N/A |
| 6/30/2020 | 2 | -877 | -406 | -263 | N/A |
| 3/31/2020 | -1 | -851 | -423 | -261 | N/A |
| 12/31/2019 | 5 | -833 | -397 | -225 | N/A |
| 9/30/2019 | 3 | -495 | -347 | -201 | N/A |
| 6/30/2019 | 1 | -157 | -298 | -177 | N/A |
| 3/31/2019 | 6 | -176 | -207 | -113 | N/A |
| 12/31/2018 | -1 | -150 | -167 | -94 | N/A |
| 12/31/2017 | 1 | -33 | -74 | -65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9966 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9966 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9966 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9966's revenue (37.5% per year) is forecast to grow faster than the Hong Kong market (8% per year).
High Growth Revenue: 9966's revenue (37.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9966 is forecast to be unprofitable in 3 years.